OBJECTIVES:The European Society of Thoracic Surgeons Lung Transplantation Working Group promoted a survey to evaluate overall sur-vival in a large cohort of patients receiving lung transplants for rare pulmonary diseases.METHODS:We conducted a retrospective multicentre study. The primary end point was overall survival; secondary end points were sur-vival of patients with the most common diagnoses in the context of rare pulmonary diseases and chronic lung allograft dysfunction(CLAD)-free survival. Finally, we analysed risk factors for overall survival and CLAD-free survival.RESULTS:Clinical records of 674 patients were extracted and collected from 13 lung transplant centres; diagnoses included 46 rare pulmo-nary diseases. Patients were followed for a median of 3.1 years. The median survival after a lung transplant was 8.5 years. The medianCLAD-free survival was 8 years. The multivariable analysis for mortality identified CLAD as a strong negative predictor [hazard ratio (HR)6.73)], whereas induction therapy was a protective factor (HR 0.68). The multivariable analysis for CLAD occurrence identified inductiontherapy as a protective factor (HR 0.51). When we stratified patients by CLAD occurrence in a Kaplan–Meier plot, the survival curves di-verged significantly (log-rank test:P< 0.001). Patients with rare diseases who received transplants had chronic rejection rates similar tothose of the general population who received transplants.CONCLUSIONS:We observed that overall survival and CLAD-free survival were excellent. We support the practice of allocating lungs topatients with rare pulmonary diseases because a lung transplant is both effective and ethically acceptable.
Rare indications for a lung transplant. A European Society of Thoracic Surgeons Survey / M. Nosotti, F. D'Ovidio, M. Leiva-Juarez, S. Keshavjee, M. Rackauskas, D. Van Raemdonck, L.J. Ceulemans, T. Krueger, A. Koutsokera, M. Schiavon, F. Rea, I. Iskender, P. Moreno, A. Alvarez, L. Luzzi, P. Paladini, L. Rosso, A. Bertani, F. Venuta, Y. Pecoraro, K. Al-Kattan, B. Kubisa, I. Inci. - In: INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY. - ISSN 1569-9293. - (2020 Oct 15). [Epub ahead of print] ((Intervento presentato al 27. convegno European Conference on General Thoracic Surgery,, 9–12 June tenutosi a Duplin (Ireland) nel 2019 [10.1093/icvts/ivaa165].
Rare indications for a lung transplant. A European Society of Thoracic Surgeons Survey
M. NosottiPrimo
;L. Rosso
;
2020
Abstract
OBJECTIVES:The European Society of Thoracic Surgeons Lung Transplantation Working Group promoted a survey to evaluate overall sur-vival in a large cohort of patients receiving lung transplants for rare pulmonary diseases.METHODS:We conducted a retrospective multicentre study. The primary end point was overall survival; secondary end points were sur-vival of patients with the most common diagnoses in the context of rare pulmonary diseases and chronic lung allograft dysfunction(CLAD)-free survival. Finally, we analysed risk factors for overall survival and CLAD-free survival.RESULTS:Clinical records of 674 patients were extracted and collected from 13 lung transplant centres; diagnoses included 46 rare pulmo-nary diseases. Patients were followed for a median of 3.1 years. The median survival after a lung transplant was 8.5 years. The medianCLAD-free survival was 8 years. The multivariable analysis for mortality identified CLAD as a strong negative predictor [hazard ratio (HR)6.73)], whereas induction therapy was a protective factor (HR 0.68). The multivariable analysis for CLAD occurrence identified inductiontherapy as a protective factor (HR 0.51). When we stratified patients by CLAD occurrence in a Kaplan–Meier plot, the survival curves di-verged significantly (log-rank test:P< 0.001). Patients with rare diseases who received transplants had chronic rejection rates similar tothose of the general population who received transplants.CONCLUSIONS:We observed that overall survival and CLAD-free survival were excellent. We support the practice of allocating lungs topatients with rare pulmonary diseases because a lung transplant is both effective and ethically acceptable.File | Dimensione | Formato | |
---|---|---|---|
Interact Cardiovasc Thorac Surg (Rare indications...).pdf
accesso riservato
Tipologia:
Altro
Dimensione
831.9 kB
Formato
Adobe PDF
|
831.9 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.